TY - JOUR
T1 - Twice-yearly exams unnecessary for patients taking quetiapine
AU - Fraunfelder, Frederick W.
N1 - Funding Information:
This study was supported in part by an unrestricted grant from Research to Prevent Blindness, New York, New York and by the National Registry of Drug-Induced Ocular Side Effects, Casey Eye Institute, Oregon Health & Science University, Portland, Oregon.
PY - 2004/11
Y1 - 2004/11
N2 - To determine the necessity for the heightened level of monitoring for cataract development in patients taking quetiapine (Seroquel, AstraZeneca Pharmaceuticals, Wilmington, Delaware) dictated by the Physicians' Desk Reference. Also, to explore the possibility of cataractogenesis because of quetiapine therapy. Observational case series. Data were garnered from a series of 80 case reports collected at the National Registry of Drug-Induced Ocular Side Effects (Portland, Oregon). The World Health Organization (WHO) causality assessment guidelines were used to assess the relationship between quetiapine and cataractogenesis. There were 34 reports of cataracts associated with quetiapine therapy. Average age was 44 years with 23 females and 11 males studied. Average duration of therapy was 29.3 weeks on standard doses. Cataractogenesis secondary to quetiapine is unlikely by WHO guidelines. This probably makes it unnecessary to require biannual ophthalmic examinations as routine eye examinations are sufficient to screen for this condition.
AB - To determine the necessity for the heightened level of monitoring for cataract development in patients taking quetiapine (Seroquel, AstraZeneca Pharmaceuticals, Wilmington, Delaware) dictated by the Physicians' Desk Reference. Also, to explore the possibility of cataractogenesis because of quetiapine therapy. Observational case series. Data were garnered from a series of 80 case reports collected at the National Registry of Drug-Induced Ocular Side Effects (Portland, Oregon). The World Health Organization (WHO) causality assessment guidelines were used to assess the relationship between quetiapine and cataractogenesis. There were 34 reports of cataracts associated with quetiapine therapy. Average age was 44 years with 23 females and 11 males studied. Average duration of therapy was 29.3 weeks on standard doses. Cataractogenesis secondary to quetiapine is unlikely by WHO guidelines. This probably makes it unnecessary to require biannual ophthalmic examinations as routine eye examinations are sufficient to screen for this condition.
UR - http://www.scopus.com/inward/record.url?scp=7544243799&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=7544243799&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2004.05.038
DO - 10.1016/j.ajo.2004.05.038
M3 - Article
C2 - 15531330
AN - SCOPUS:7544243799
SN - 0002-9394
VL - 138
SP - 870
EP - 871
JO - American journal of ophthalmology
JF - American journal of ophthalmology
IS - 5
ER -